Investigation Launched Into Sage Therapeutics, Inc. (SAGE)
The Law Offices of Frank R. Cruz have opened an investor-focused investigation into Sage Therapeutics, Inc. (SAGE). The inquiry centers on concerns that Sage may have violated federal securities laws, raising potential risks for shareholders who relied on the company’s statements and recent disclosures.
Setbacks and the Market’s Reaction
Investor attention sharpened in the summer of 2023, when Sage announced that the FDA had approved its drug zuranolone solely for postpartum depression (PPD). At the same time, the FDA issued a Complete Response Letter (CRL) for the drug’s use in major depressive disorder (MDD), stating that the application lacked substantial evidence of effectiveness. The market response was swift: Sage’s stock price fell by more than 53% over just a few days.
August 7, 2023: Immediate Impact
On August 7, 2023, Sage’s shares dropped sharply from $36.10 to $16.75. The move forced many investors to reassess expectations for the company’s depression franchise and its regulatory path forward. Questions mounted about timing, strategy, and what would come next.
Clinical Updates Deepen Investor Concerns
Momentum didn’t improve in 2024. On April 17, 2024, Sage reported that its Phase 2 study of SAGE-718—designed to address mild cognitive impairment associated with Parkinson’s disease—did not meet its primary endpoint. The stock fell again, closing at $12.57 per share, a 19.6% decline that day, as investors absorbed another setback to the pipeline.
Essential Tremor Study and July 24, 2024 Reaction
Further pressure arrived on July 24, 2024, when the company disclosed that its Phase 2 study of Sage-324 for essential tremor (ET) showed no statistically significant results. Sage said it would not continue clinical development for that program. The stock slid again, ending the day at $10.38 per share.
What This Means for Investors
These developments—an FDA CRL for MDD, followed by multiple trial disappointments—have left many shareholders weighing their options. If you’ve experienced losses, it’s important to stay current on the investigation and understand what rights and potential remedies might apply to you. Knowing where you stand can help you decide your next step with more clarity.
How to Get Help
If you have relevant information, questions, or need guidance tailored to your situation, consider contacting The Law Offices of Frank R. Cruz. The firm, based in California, can be reached by phone or through its website to discuss your investment and possible legal options.
Frequently Asked Questions
Why is Sage Therapeutics under investigation?
The investigation focuses on potential violations of federal securities laws tied to Sage’s recent announcements, including the FDA’s limited approval of zuranolone and subsequent clinical trial results that did not meet key goals.
What did the FDA decide about zuranolone, and why did it matter?
The FDA approved zuranolone only for postpartum depression (PPD) and issued a Complete Response Letter (CRL) for major depressive disorder (MDD), citing a lack of substantial evidence of effectiveness. That split outcome significantly affected investor expectations and the stock price.
How did the stock react to the FDA news and later trial updates?
Following the FDA’s decision in the summer of 2023, the stock fell by more than 53% within days, including a drop from $36.10 to $16.75 on August 7, 2023. In 2024, shares declined again after Phase 2 updates—closing at $12.57 on April 17 and $10.38 on July 24.
What were the key clinical trial outcomes mentioned?
SAGE-718, studied for mild cognitive impairment related to Parkinson’s disease, did not meet its primary endpoint in Phase 2. Sage-324, in a Phase 2 study for essential tremor, showed no statistically significant results, and Sage said it would not continue clinical development for that program.
What can I do if I’m an investor who suffered losses?
Stay informed about the investigation and consider reaching out to The Law Offices of Frank R. Cruz for guidance on your rights and potential options related to these events.
